(Q33707711)

28 July 2017

1 reference

title

Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia (English)

1 reference

28 July 2017

0 references

Ikwunga Wonodi

1

1 reference

PubMed ID

20147364

28 July 2017

Robert Schwarcz

series ordinal

2

1 reference

PubMed ID

20147364

28 July 2017

language of work or name

English

0 references

publication date

10 February 2010

1 reference

28 July 2017

Schizophrenia Bulletin

1 reference

28 July 2017

36

1 reference

28 July 2017

2

1 reference

28 July 2017

211-218

1 reference

Activation of brain interleukin-1beta in schizophrenia.

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Common variants conferring risk of schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Mammalian nicotinic acetylcholine receptors: from structure to function

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Biochemical and structural properties of mouse kynurenine aminotransferase III

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Realistic expectations of prepulse inhibition in translational models for schizophrenia research

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Initial phase 2 trial of a nicotinic agonist in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

From inflammation to sickness and depression: when the immune system subjugates the brain

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Schizophrenia endophenotypes as treatment targets

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Hippocampal long-term synaptic plasticity and signal amplification of NMDA receptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Refining the predictive pursuit endophenotype in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Schizophrenia and the alpha7 nicotinic acetylcholine receptor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Elevations of endogenous kynurenic acid produce spatial working memory deficits

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

The primacy of cognition in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Direct assessment of functional abilities: relevance to persons with schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Identification of separable cognitive factors in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

The endophenotype concept in psychiatry: etymology and strategic intentions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Increased cortical kynurenate content in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

The current status of the dopamine hypothesis of schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Synthesis and metabolism of L-kynurenine in rat brain

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Monoamine Mechanisms in Chronic Schizophrenia: Post-Mortem Neurochemical Findings

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program.

21 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Spatial working memory deficits in the relatives of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Effects of repeated amphetamine administration on antisaccade in schizophrenia spectrum personality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Metabolic control of kynurenic acid formation in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Identification of tryptophan 2,3-dioxygenase RNA in rodent brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Micromolar Brain Levels of Kynurenic Acid are Associated with a Disruption of Auditory Sensory Gating in the Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Endogenous kynurenic acid disrupts prepulse inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Galantamine for the treatment of cognitive impairments in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ002

Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

A mechanism for increased quinolinic acid formation following acute systemic immune stimulation.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833131

The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20147364

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cognitive deficits as treatment targets in schizophrenia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20147364

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Modulators of the Kynurenine Pathway of Tryptophan Metabolism: Synthesis and Preliminary Biological Evaluation of (S)-4-(Ethylsulfonyl)benzoylalanine, a Potent and Selective Kynurenine Aminotransferase II (KAT II) Inhibitor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20147364

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/SCHBUL/SBQ002

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

PubMed ID

20147364